Edition:
United States

Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Myelodysplastic Syndromes


Monday, 4 Jun 2018 07:00am EDT 

June 4 (Reuters) - Acceleron Pharma Inc ::ACCELERON ANNOUNCES UPDATED RESULTS FROM ONGOING PHASE 2 TRIALS OF LUSPATERCEPT IN MYELODYSPLASTIC SYNDROMES AT THE ASCO 2018 ANNUAL MEETING.ACCELERON PHARMA INC - 55% OF PATIENTS ACHIEVED A CLINICALLY MEANINGFUL ERYTHROID IMPROVEMENT.ACCELERON PHARMA INC - 44% OF PATIENTS WITH A RED BLOOD CELL TRANSFUSION BURDEN AT BASELINE ACHIEVED TRANSFUSION INDEPENDENCE.ACCELERON PHARMA INC - MULTIPLE PATIENTS CONTINUE TO SUSTAIN CLINICALLY MEANINGFUL INCREASE IN HEMOGLOBIN AND REDUCTION IN TRANSFUSION BURDEN.